Last reviewed · How we verify
HL151
HL151 is an investigational therapeutic agent in phase 3 development by Hanlim Pharm, with mechanism details not publicly disclosed.
At a glance
| Generic name | HL151 |
|---|---|
| Sponsor | Hanlim Pharm. Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Limited public information is available regarding HL151's specific mechanism of action. As a phase 3 candidate from Hanlim Pharm, it has progressed through early clinical evaluation, but detailed mechanistic data has not been widely published in accessible pharmaceutical databases or literature.
Approved indications
Common side effects
Key clinical trials
- To Evaluate the Efficacy and Safety of HL151 Versus Placebo in Perennial Allergic Rhinitis Patients (PHASE3)
- Evaluate the Efficacy and Safety of HL151 Versus Talion Tab. in Pruritus Cutaneus (PHASE3)
- Repeated Dosing Clinical Trial of HL151 (PHASE1)
- Single Dosing Clinical Trial of HL151 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |